Phoebe Li

Dr. Phoebe Li

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2023 in Journal of Medical Internet Research
Verified
Journal Article
Open access
SGStephen Gilbert
Stephen Gilbert
SAStuart Anderson
Stuart Anderson
MDMartin Daumer
Martin Daumer
PLPhoebe Li
Phoebe Li
TMTom Melvin
Tom Melvin
RWRobin Williams
Robin Williams
Artificial intelligence (AI) and machine learning medical tools have the potential to be transformative in care delivery; however, this change will only be realized if accompanied by effective governance that ensures patient safety and public trust. Recent digital health initiatives have called for tighter governance of digital health. A correct balance must be found between ensuring product safety and performance while also enabling the innovation needed to deliver better approaches for patients and affordable efficient health care for society. This requires innovative, fit-for-purpose approaches to regulation. Digital health technologies, particularly AI-based tools, pose specific challenges to the development and implementation of functional regulation. The approaches of regulatory science and “better regulation” have a critical role in developing and evaluating solutions to these problems and ensuring effective implementation. We describe the divergent approaches of the European Union and the United States in the implementation of new regulatory approaches in digital health, and we consider the United Kingdom as a third example, which is in a unique position of developing a new post-Brexit regulatory framework.

2 January 2020 in Law, Innovation and Technology
Verified
Journal Article
Closed access
PLPhoebe Li
Phoebe Li
AFAlex Faulkner
Alex Faulkner
NMNicholas Medcalf
Nicholas Medcalf
In this paper we assess both the ex ante and the ex post dimensions of the regulatory landscape of 3D bioprinting governance. While the former is mainly concerned with the market approval and safety of 3D bioprinting, the latter is concerned with the matter of liability once bioprinting has been licensed or authorised for use. In this 2D landscape, we highlight three sets of choices: whether regulation should focus on the process, the product or both; whether to rely on existing regimes or create a new bespoke and distinct regulatory framework; and whether to employ top down, bottom up, or co-regulation. We identify a series of interpretative uncertainties as well as gaps in the current legal regimes. We consider an initial provisional ‘process-based’ approach and a co-regulation model for bioprinting governance. We anticipate that the study of the regulatory landscape will offer key insights in relation to other types of biofabrication.

21 November 2023 in Law, Technology and Humans
Verified
Journal Article
Open access
PDF file
PLPhoebe Li
Phoebe Li
RWRobin Williams
Robin Williams
SGStephen Gilbert
Stephen Gilbert
SAStuart Anderson
Stuart Anderson
Recent achievements in respect of Artificial Intelligence (AI) open up opportunities for new tools to assist medical diagnosis and care delivery. However, the typical process for the development of AI is through repeated cycles of learning and implementation, something that poses challenges to our existing system of regulating medical devices. Product developers face tensions between the benefits of continuous improvement/deployment of algorithms and keeping products unchanged. The latter more easily facilitates collecting evidence for safety assurance processes but sacrifices optimisation of performance and adaptation to user needs gained through learning-implementation cycles. The challenge is how to balance potential benefits with the need to assure their safety. Governance and assurance processes are needed that can accommodate real-time or near-real-time machine learning. Such an approach is of great importance in healthcare and other fields of application. AI has stimulated an intense process of learning as this new technology embeds in application contexts. The process is not only about the application of AI in the real world but also about the institutional arrangements for its safe and dependable deployment, including regulatory experimentation involving new market pathways, monitoring and surveillance, and sandbox schemes. We review the key themes, challenges and potential solutions raised at two stakeholder workshops and highlight recent attempts to adapt the laws for AI-enabled medical devices (AIeMD) with a special focus on the regulatory proposals in the UK and internationally. The UK regulatory trajectory shows signs of alignment with the US thinking, and yet the European Union model is still the most closely aligned framework.

31 December 2014 in Law, Innovation and Technology
Verified
Journal Article
Closed access
PLPhoebe Li
Phoebe Li
(2014). 3D Bioprinting Technologies: Patents, Innovation and Access. Law, Innovation and Technology: Vol. 6, No. 2, pp. 282-304.

2 January 2014 in Journal of Intellectual Property Law and Practice
Verified
Journal Article
Open access
PDF file
PLPhoebe Li
Phoebe Li
SMStephen Mellor
Stephen Mellor
JGJames Griffin
James Griffin
CWCharlotte Waelde
Charlotte Waelde
LHLiang Hao
Liang Hao
RERichard Everson
Richard Everson
Phoebe Li is a Lecturer at Sussex University. Stephen Mellor, James Griffin, Charlotte Waelde, Liang Hao, and Richard Everson are based at Exeter University. The emergence of 3D printing technology as a ‘disruptive technology’ challenges the existing intellectual property framework. Our paper considers one part of that framework - copyright - in the light of 3D printing, with a special focus on issues involving artistic works and liability for authorisation of infringement of copyright. We consider a scenario concerning consumer co-creation arising from 3D chocolate printing technology developed at Exeter University. We discuss the production of two-dimensional artistic works into three dimensions; ownership; originality and substantial copying; authorship, term of protection, and authorisation of infringement. We consider different business models for co-creation of 3D printing technology. We conclude that by resorting to collective bargaining mechanisms and collective licensing schemes akin to those developed in the UK and in Europe, the co-creators could be rewarded through mechanisms akin to benefit sharing.

1 March 2017 in European Journal of Risk Regulation
Verified
Journal Article
Open access
PDF file
PLPhoebe Li
Phoebe Li
AFAlex Faulkner
Alex Faulkner
This report introduces the challenges 3D bioprinting poses to the existing legal regime across bioethics, safety, regenerative medicine, and tissue engineering. We briefly review the 3D bioprinting technology and look into the relevant regulatory instruments for the pre-printing, printing, and post-printing stages. Special attention is paid to the applications of the EU Advanced Therapy Medicinal Products Regulation and the new Medical Device Regulation.